Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab.
Ulf LandmesserJennifer McGinnissPh Gabriel StegDeepak L BhattVera A BittnerRafael DiazMirza DilicShaun G GoodmanJ Wouter JukemaMegan LoyIvan PećinRobert PordySteen H PoulsenMichael SzarekHarvey D WhiteGregory G Schwartznull nullPublished in: European journal of preventive cardiology (2022)
Among patients with recent ACS and LDL-C ≥1.4 mmol/L despite optimized statin therapy, the addition of alirocumab allowed 94.6% to achieve the 2019 European guideline LDL-C goal <1.4 mmol/L, and 85.2% of those with recurrent cardiovascular events to achieve <1.0 mmol/L. In contrast, the addition of ezetimibe to optimized statin therapy was projected to achieve LDL-C <1.4 mmol/L in only 10.6% of patients at baseline.
Keyphrases
- low density lipoprotein
- cardiovascular events
- acute coronary syndrome
- coronary artery disease
- cardiovascular disease
- percutaneous coronary intervention
- antiplatelet therapy
- magnetic resonance
- magnetic resonance imaging
- climate change
- stem cells
- computed tomography
- type diabetes
- contrast enhanced
- replacement therapy
- cell therapy
- smoking cessation
- global health